Abstract Aims To determine whether adults with type 2 diabetes (T2D) treated with retatrutide report greater changes in selfreported appetite, dietary restraint, and disinhibition compared to placebo or dulaglutide and to examine associations with weight change
, 1 % 39,34 (29/0,737), 92,59 (55 /0,594), 0,424 (39,34/92,59)
Phase 2 trial data published in the New England Journal of Medicine showed an average of 24.2% body weight reduction at the highest research quantities over 48 weeks
Drug Discov Today
Phase 2 Trial Results: The Numbers Behind the Hype The Phase 2 data for Retatrutide was published in the New England Journal of Medicine and represents the most discussed set of results in obesity pharmacology in recent years
You Don't Have to Wait for Retatrutide to Protect Muscle While retatrutide's body composition data is promising, the reality is that you can address muscle preservation right now by combining current GLP-1 medications with hormone optimization and peptide therapy
